India’s DengiAll Vaccine Trial Reaches 70% Enrollment
Researchers have enrolled over 7,000 volunteers across 20 sites with final recruitment concentrated at AIIMS Bibinagar to wrap up safety and immunogenicity assessments
Overview
- Over 7,000 participants—around 70% of the 10,000-volunteer cohort—have been enrolled in the Phase III clinical trial
- The randomized, double-blind, placebo-controlled study assesses safety, immunogenicity and efficacy of the single-dose live attenuated tetravalent vaccine DengiAll
- Sites span 20 centers nationwide with AIIMS Bibinagar emerging as a key hub for the trial’s final recruitment phase under lead investigator Dr Rashmi Kundapur
- Panacea Biotec is developing the vaccine under a licensing agreement with the NIH, with ICMR oversight and an estimated budget of Rs 1.3–1.5 crore allocated per site
- Data collection and monitoring remain on schedule for the projected October 2025 completion as India pursues its first licensed dengue vaccine